Charleston Laboratories, Inc. Resubmits NDA for CL-108
Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108,for Acute Pain and Opioid-Induced Nausea and Vomiting
Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary
Prescription for Success
It was in late 2005 when a seemingly simple idea hit Charleston Laboratories founder and CEO Paul Bosse like a ton of bricks.
From a clinical standpoint, pain is the most common and demanding symptom to treat.
Raymond A. Dionne D.D.S., Ph.D Joins Charleston Laboratories